Form 8-K - Current report:
SEC Accession No. 0001193125-21-170821
Filing Date
2021-05-24
Accepted
2021-05-24 16:01:30
Documents
12
Period of Report
2021-05-21
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d107005d8k.htm   iXBRL 8-K 34760
  Complete submission text file 0001193125-21-170821.txt   157731

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kpti-20210521.xsd EX-101.SCH 3093
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20210521_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20210521_pre.xml EX-101.PRE 11423
5 EXTRACTED XBRL INSTANCE DOCUMENT d107005d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 21954760
SIC: 2834 Pharmaceutical Preparations